España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ligand Pharmaceuticals
LGND
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$116.55
4.99
4.47%
At close: -
$116.55
0
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Ligand Pharmaceuticals (LGND) Forecast
News
Earnings
Ligand Pharmaceuticals (LGND) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Ligand Pharmaceuticals (NASDAQ:LGND) Stock
Ligand Pharmaceuticals Stock (NASDAQ: LGND)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, November 12, 2024
RBC Capital Maintains Outperform on Ligand Ph...
Benzinga Newsdesk
Friday, November 08, 2024
Benchmark Maintains Buy on Ligand Pharmaceuti...
Benzinga Newsdesk
Barclays Maintains Overweight on Ligand Pharm...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Ligand Ph...
Benzinga Newsdesk
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Ligand ...
Benzinga Newsdesk
Thursday, November 07, 2024
Ligand Pharmaceuticals shares are trading hig...
Benzinga Newsdesk
Ligand Pharmaceuticals Raises FY24 Adj EPS Gu...
Benzinga Newsdesk
Ligand Pharmaceuticals Q3 2024 Adj. EPS $1.84...
Benzinga Newsdesk
Thursday, October 31, 2024
HC Wainwright & Co. Reiterates Buy on Ligand ...
Benzinga Newsdesk
Monday, October 28, 2024
Barclays Maintains Overweight on Ligand Pharm...
Benzinga Newsdesk
Monday, October 21, 2024
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
Benzinga Insights
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Ligand P...
Benzinga Newsdesk
Thursday, October 03, 2024
The Latest Analyst Ratings For Ligand Pharmaceuticals
Benzinga Insights
Oppenheimer Initiates Coverage On Ligand Phar...
Benzinga Newsdesk
Wednesday, September 25, 2024
Insider Move: Matthew E Korenberg Exercises Options, Realizing $704K At Ligand Pharmaceuticals
Benzinga Insights
Friday, September 20, 2024
Breaking Update: Octavio Espinoza Engages In Options Exercise At Ligand Pharmaceuticals
Benzinga Insights
Thursday, September 19, 2024
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K
Benzinga Insights
Friday, September 06, 2024
Ligand Partner Travere Therapeutics Receives ...
Benzinga Newsdesk
Tuesday, August 27, 2024
Insider Transaction: Matthew E Korenberg Sells $1.99M Worth Of Ligand Pharmaceuticals Shares
Benzinga Insights
Friday, August 16, 2024
Looking Into Ligand Pharmaceuticals's Recent Short Interest
Benzinga Insights
Monday, August 12, 2024
Benchmark Maintains Buy on Ligand Pharmaceuti...
Benzinga Newsdesk
RBC Capital Reiterates Outperform on Ligand P...
Benzinga Newsdesk
Thursday, August 08, 2024
HC Wainwright & Co. Reiterates Buy on Ligand ...
Benzinga Newsdesk
Wednesday, August 07, 2024
RBC Capital Reiterates Outperform on Ligand P...
Benzinga Newsdesk
Tuesday, August 06, 2024
Ligand Sees 2024 Core Adj. EPS $5.00-$5.50 vs...
Benzinga Newsdesk
Ligand Pharmaceuticals Q2 2024 Adj. EPS $1.40...
Benzinga Newsdesk
Tuesday, July 30, 2024
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
Benzinga Insights
RBC Capital Initiates Coverage On Ligand Phar...
Benzinga Newsdesk
Tuesday, July 09, 2024
Craig-Hallum Maintains Buy on Ligand Pharmace...
Benzinga Newsdesk
Monday, July 08, 2024
HC Wainwright & Co. Reiterates Buy on Ligand ...
Benzinga Newsdesk
Ligand Pharma to Acquire APEIRON Biologics AG...
Benzinga Newsdesk
Friday, June 28, 2024
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
Benzinga Insights
Benchmark Reiterates Buy on Ligand Pharmaceut...
Benzinga Newsdesk
Thursday, June 27, 2024
HC Wainwright & Co. Reiterates Buy on Ligand ...
Benzinga Newsdesk
Ligand Pharmaceuticals Announces FDA Approval...
Benzinga Newsdesk
Friday, June 21, 2024
Gilead Up as Twice-Yearly HIV Shot Prevents Infection
Zacks
Tuesday, June 18, 2024
FDA Approves CAPVAXIVE, Sixth Product Using P...
Benzinga Newsdesk
Thursday, May 23, 2024
Bristol Myers Updates Action Date for Subcutaneous Opdivo
Zacks
Wednesday, May 22, 2024
Roche Cancer Drug Gets Breakthrough Therapy Designation
Zacks
Friday, May 17, 2024
Ionis, Biogen Down on Ending Development of ALS Drug
Zacks
Thursday, May 16, 2024
Ligand Pharmaceuticals President & Chief Operating Trades $1.50M In Company Stock
Benzinga Insights
Tuesday, May 14, 2024
Merck Ends Keytruda Combo Melanoma Study Due to Futility
Zacks
Ligand Moves to Strong Buy: Rationale Behind the Upgrade
Zacks
Thursday, May 09, 2024
Perrigo Q1 Earnings Surpass, Sales Miss Estimates
Zacks
Wednesday, May 08, 2024
HC Wainwright & Co. Reiterates Buy on Ligand ...
Benzinga Newsdesk
Tuesday, May 07, 2024
Ligand Pharmaceuticals Reaffirms FY24 Adj. EP...
Benzinga Newsdesk
Ligand Pharmaceuticals Q1 2024 Adj EPS $3.84 ...
Benzinga Newsdesk
Ligand And Agenus Enter Into $100M Royalty Fi...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch